Development of Autoimmune Diseases Among Children With Pediatric Acute-Onset Neuropsychiatric Syndrome.


Journal

JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235

Informations de publication

Date de publication:
01 Jul 2024
Historique:
medline: 30 7 2024
pubmed: 30 7 2024
entrez: 30 7 2024
Statut: epublish

Résumé

Epidemiologic studies indicate a high rate of autoimmune conditions among patients with obsessive-complusive disorder and other psychiatric conditions. Furthering the understanding of the inflammatory diatheses of psychiatric conditions may open doors to new treatment paradigms for psychiatric disorders. To evaluate whether pediatric acute-onset neuropsychiatric syndrome (PANS) is associated with an inflammatory diathesis by assessing signs of immune activation and vasculopathy during a psychiatric symptom exacerbation (flare), estimating the risk of developing arthritis and other autoimmune diseases, and characterizing subtypes of arthritis. This retrospective cohort study used longitudinal clinical data on 193 consecutive patients with PANS followed up within the Stanford Immune Behavioral Health Clinic from September 1, 2012, to December 31, 2021. Medical records were reviewed, and a predefined set of immune markers that were measured during a flare and the features and imaging findings of arthritis and other autoimmune diseases were collected. Immune activation markers included (1) autoimmunity signs (antinuclear antibody, antihistone antibody, antithyroglobulin antibody, C1q binding assay, and complement levels [C3 and C4]); (2) immune dysregulation or inflammation signs (leukopenia, thrombocytosis, C-reactive protein, and erythrocyte sedimentation rate); and (3) vasculopathy signs (livedo reticularis, periungual redness and swelling, abnormally prominent onychodermal band, palatal petechiae, high von Willebrand factor antigen, and high d-dimer). Last, the cumulative risk of developing arthritis and autoimmune diseases was estimated using product limit (Kaplan-Meier) survival probability. The study included data from 193 children (112 boys [58.0%]) who had PANS at a mean (SD) age of 7.5 (3.5) years. They were followed up for a mean (SD) of 4.0 (2.1) years. Among those tested for immune activation markers, 54.2% (97 of 179) had nonspecific markers of autoimmunity, 12.0% (22 of 184) had nonspecific signs of immune dysregulation or inflammation, and 35.8% (69 of 193) had signs of vasculopathy. By 14 years of age, the estimated cumulative incidence of arthritis was 28.3% (95% CI, 20.8%-36.3%), and the estimated cumulative incidence of another autoimmune disease was 7.5% (95% CI, 4.0%-12.4%). Novel findings in the subgroup with arthritis include joint capsule thickening (55.0% [22 of 40]), distal interphalangeal joint tenderness (81.8% [45 of 55]), and spinous process tenderness (80.0% [44 of 55]). Among the 55 patients with arthritis, the most common subtypes of arthritis included enthesitis-related arthritis (37 [67.3%]), spondyloarthritis (27 [49.1%]), and psoriatic arthritis (10 [18.2%]). This study found that patients with PANS show signs of immune activation and vasculopathy during psychiatric symptom flares and have an increased risk of developing arthritis and other autoimmune diseases compared with the general pediatric population. The most common arthritis subtype was enthesitis-related arthritis. These findings suggest that PANS may be part of a multisystem inflammatory condition rather than an isolated psychiatric or neuroinflammatory disorder.

Identifiants

pubmed: 39078633
pii: 2821657
doi: 10.1001/jamanetworkopen.2024.21688
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2421688

Auteurs

Meiqian Ma (M)

Division of Allergy, Immunology, & Rheumatology, Department of Pediatrics, Stanford University School of Medicine, Palo Alto, California.
Stanford Immune Behavioral Health Clinic and Research Program at Lucile Packard Children's Hospital, Palo Alto, California.

Erin E Masterson (EE)

Department of Environmental & Occupational Health Sciences, School of Public Health, University of Washington, Seattle.

Jaynelle Gao (J)

Division of Allergy, Immunology, & Rheumatology, Department of Pediatrics, Stanford University School of Medicine, Palo Alto, California.
Stanford Immune Behavioral Health Clinic and Research Program at Lucile Packard Children's Hospital, Palo Alto, California.

Hannah Karpel (H)

Division of Allergy, Immunology, & Rheumatology, Department of Pediatrics, Stanford University School of Medicine, Palo Alto, California.
Stanford Immune Behavioral Health Clinic and Research Program at Lucile Packard Children's Hospital, Palo Alto, California.

Avis Chan (A)

Division of Allergy, Immunology, & Rheumatology, Department of Pediatrics, Stanford University School of Medicine, Palo Alto, California.
Stanford Immune Behavioral Health Clinic and Research Program at Lucile Packard Children's Hospital, Palo Alto, California.

Rajdeep Pooni (R)

Division of Allergy, Immunology, & Rheumatology, Department of Pediatrics, Stanford University School of Medicine, Palo Alto, California.

Jesse Sandberg (J)

Pediatric Division of Radiology, Stanford University School of Medicine, Palo Alto, California.

Erika Rubesova (E)

Pediatric Division of Radiology, Stanford University School of Medicine, Palo Alto, California.

Bahare Farhadian (B)

Stanford Immune Behavioral Health Clinic and Research Program at Lucile Packard Children's Hospital, Palo Alto, California.

Theresa Willet (T)

Division of Allergy, Immunology, & Rheumatology, Department of Pediatrics, Stanford University School of Medicine, Palo Alto, California.
Stanford Immune Behavioral Health Clinic and Research Program at Lucile Packard Children's Hospital, Palo Alto, California.

Yuhuan Xie (Y)

Stanford Immune Behavioral Health Clinic and Research Program at Lucile Packard Children's Hospital, Palo Alto, California.
Division of Child & Adolescent Psychiatry, Department of Psychiatry, Stanford University School of Medicine, Palo Alto, California.

Paula Tran (P)

Stanford Immune Behavioral Health Clinic and Research Program at Lucile Packard Children's Hospital, Palo Alto, California.
Division of Child & Adolescent Psychiatry, Department of Psychiatry, Stanford University School of Medicine, Palo Alto, California.

Melissa Silverman (M)

Stanford Immune Behavioral Health Clinic and Research Program at Lucile Packard Children's Hospital, Palo Alto, California.
Division of Child & Adolescent Psychiatry, Department of Psychiatry, Stanford University School of Medicine, Palo Alto, California.

Margo Thienemann (M)

Stanford Immune Behavioral Health Clinic and Research Program at Lucile Packard Children's Hospital, Palo Alto, California.
Division of Child & Adolescent Psychiatry, Department of Psychiatry, Stanford University School of Medicine, Palo Alto, California.

Elizabeth Mellins (E)

Department of Pediatrics, Program in Immunology, Stanford University School of Medicine, Palo Alto, California.

Jennifer Frankovich (J)

Division of Allergy, Immunology, & Rheumatology, Department of Pediatrics, Stanford University School of Medicine, Palo Alto, California.
Stanford Immune Behavioral Health Clinic and Research Program at Lucile Packard Children's Hospital, Palo Alto, California.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH